Clover Biopharmaceuticals Ltd
HKEX:2197
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
C
|
Clover Biopharmaceuticals Ltd
HKEX:2197
|
2.9B HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
405B USD |
Loading...
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
71.4B AUD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Clover Biopharmaceuticals Ltd
Glance View
Clover Biopharmaceuticals Ltd. engages in the research and development of biopharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 814 full-time employees. The company went IPO on 2021-11-05. The firm's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The firm's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Clover Biopharmaceuticals Ltd is -1 756.9%, which is above its 3-year median of -53 270.3%.
Over the last 2 years, Clover Biopharmaceuticals Ltd’s Net Margin has increased from -258 830.4% to -1 756.9%. During this period, it reached a low of -258 830.4% on Jun 30, 2023 and a high of -352.9% on Dec 31, 2023.
